Table 2. NCD medicines in secondary analysis of availability and affordability.
| Medicine, strength and dosage form | Percentage of surveys with medicine(n = no. of surveys) | No. units for affordability analysis(30 days’ supply) |
|---|---|---|
| Medicines for cardiovascular diseases | ||
| Furosemide 40mg cap/tab | 83.3% (n = 25) | 30 |
| Atenolol 50mg cap/tab* | 73.3% (n = 22) | 30 |
| Enalapril 5mg,10mg and 20mg cap/tab* | 70.0% (n = 21) | 30 |
| Simvastatin 20mg cap/tab* | 66.7% (n = 20) | 30 |
| Captopril 25mg cap/tab* | 63.3% (n = 19) | 60 |
| Amlodipine 5mg cap/tab | 46.7% (n = 14) | 30 |
| Hydrochlorothiazide 25mg cap/tab* | 46.7% (n = 14) | 30 |
| Atorvastatin 10mg and 20mg cap/tab* | 30.0% (n = 9) | 30 |
| Nifedipine Retard 20mg tab* | 30.0% (n = 9) | 60 |
| Digoxin 0.25mg cap/tab | 30.0% (n = 9) | 30 |
| Acetylsalicyclic acid 100mg cap/tab* | 26.7% (n = 8) | 30 |
| Losartan 50mg cap/tab | 20.0% (n = 6) | 30 |
| Propranolol 40mg cap/tab* | 16.7% (n = 5) | 120 |
| Isosorbide dinitrate 10mg cap/tab | 13.3% (n = 4) | 180 |
| Lisinopril 10mg cap/tab* | 10.0% (n = 3) | 30 |
| Medicines for diabetes | ||
| Glibenclamide 5mg cap/tab | 93.3% (n = 28) | 60 |
| Metformin 500mg and 850mg cap/tab* | 76.7% (n = 23) | 500mg 90; 850mg 60 |
| Insulin human, soluble, isophane and 30/70, 100IU/ml vial* | 30.0% (n = 9) | 10ml |
| Gliclazide 80mg cap/tab | 13.3% (n = 4) | 30 |
| Medicines for chronic obstructive pulmonary diseases (COPD) | ||
| Salbutamol 100mcg/dose inhaler* | 96.7% (n = 29) | 200 doses |
| Beclometasone 50mcg/dose, 100mcg/dose and 250mcg/dose inhaler* | 56.7% (n = 17) | 200 doses |
| Budesonide 100mcg/dose and 200mcg/dose inhaler* | 10.0% (n = 3) | 200 doses |
| Ipratropium 20mcg/dose inhaler* | 3.3% (n = 1) | 200 doses |
| Salbutamol 2mg and 4mg cap/tab | 13.3% (n = 4) | 2mg 180; 4mg 90 |
| Medicines for central nervous system (CNS) conditions: antipsychotics, medicines for anxiety, depression, epilepsy and Parkinson’s Disease | ||
| Amitriptyline 25mg cap/tab | 96.7% (n = 29) | 90 |
| Diazepam 5mg and 10mg cap/tab | 83.3% (n = 25) | 7 |
| Carbamazepine 200mg cap/tab | 76.7% (n = 23) | 150 |
| Fluoxetine 20mg cap/tab | 53.3% (n = 16) | 30 |
| Phenytoin 100mg cap/tab | 43.3% (n = 13) | 90 |
| Clonazepam 2mg cap/tab | 23.3% (n = 7) | 120 |
| Phenobarbital 100mg and 30mg cap/tab | 16.7% (n = 5) | 100mg 30;30mg 90 |
| Clozapine 100mg cap/tab | 13.3% (n = 4) | 90 |
| Sodium valproate 200mg and valproic acid 150mg cap/tab | 10.0% (n = 3) | 200mg 150; 150mg 200 |
| Risperidone 2mg cap/tab | 6.7% (n = 2) | 60 |
| Imipramine 25mg cap/tab | 6.7% (n = 2) | 120 |
| Levodopa+carbidopa 25+250mg cap/tab | 6.7% (n = 2) | 120 |
* Belong to the classes of NCD medicines in the GAP report considered necessary to provide basic cost-effective primary healthcare